Rigel Pharmaceuticals (RIGL) 4.24 $RIGL
The Zacks Analyst Blog Highlights: Rigel Pharmaceuticals, Exelixis and Atlas Resource Partners - Press Releases
Zacks Equity Research - Zacks Investment Research - Mon Apr 20, 8:30AM CDT
The Zacks Analyst Blog Highlights: Rigel Pharmaceuticals, Exelixis and Atlas Resource Partners
RIGL: 4.24 (+0.07), ARP: 9.04 (-0.02), EXEL: 3.12 (+0.05)
3 Momentum Picks Under $10 to Sail the Turbulent Market - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 17, 10:57AM CDT
When you combine a momentum strategy with small-cap stocks, the likelihood of gains is exponential.
RIGL: 4.24 (+0.07), EXEL: 3.12 (+0.05), ARP: 9.04 (-0.02)
Therapy Focus - Beyond Blood Pressure Control For IgA Nephropathy
EP Vantage - Seeking Alpha - Thu Apr 16, 3:54PM CDT
Phase II data from the Swedish group Pharmalink in the autoimmune disorder IgA nephropathy has shone a light on a rare, little-known condition that has no disease-modifying treatments. Tight blood pressure control to minimise the damage from the...
CCXI: 7.86 (-0.02), RIGL: 4.24 (+0.07)
BUYINS.NET: OTIV, JKD, BR, FLO, AIN, RIGL Are Seasonally Ripe To Go Up In the Next Five Weeks
M2 - Fri Apr 10, 6:59AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of On Track Innovations Ltd (NASDAQ:OTIV), iShares Morningstar Large Core Index Fund (NYSE:JKD), Big Rock Brewery Inc (NYSE:BR), Flowers Foods Inc (NYSE:FLO), Albany International Corp (NYSE:AIN), Rigel Pharmaceuticals Inc (NASDAQ:RIGL) and each have a high seasonal probability to go Up in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:
AIN: 40.36 (+0.02), BR: 53.55 (-0.04), OTIV: 1.58 (+0.03), RIGL: 4.24 (+0.07), FLO: 22.50 (-0.03), JKD: 123.64 (+0.72)
Can the Rally in Rigel Pharmaceuticals (RIGL) Shares Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Apr 09, 8:07AM CDT
Can the Rally in Rigel Pharmaceuticals (RIGL) Shares Continue?
RIGL: 4.24 (+0.07)
Healthcare stock screen of the month: Price extended, poor fundamentals
Seeking Alpha - at Seeking Alpha - Wed Apr 08, 12:05PM CDT
CRMD: 8.86 (-0.28), ADXS: 22.18 (+0.10), CYTX: 0.96 (-0.09), CNDO: 4.09 (-0.09), AMRN: 2.34 (-0.05), AVEO: 2.04 (+0.12), NVGN: 7.40 (-0.30), AXN: 1.77 (+0.01), NYMX: 1.32 (-0.08), DRRX: 2.19 (+0.10), RIGL: 4.24 (+0.07), CAPN: 6.99 (-0.29)
Technical Report on Biotech Stocks - Athersys, Dyax Corp., Rigel Pharma, Regeneron Pharma, and BioCryst Pharma
PR Newswire - Mon Apr 06, 7:55AM CDT
Editor Note: For more information about this release, please scroll to bottom.
BCRX: 10.62 (-0.09), ATHX: 1.34 (+0.01), RIGL: 4.24 (+0.07), REGN: 472.63 (+9.41), DYAX: 28.12 (+0.15)
Rigel Pharmaceuticals (RIGL) Looks Good: Stock Up 6.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Apr 01, 7:30AM CDT
Rigel Pharmaceuticals, Inc. (RIGL) was a big mover last session, as the company saw its shares rise roughly 7% on the day.
FLML: 15.84 (-0.33), RIGL: 4.24 (+0.07)
Why Rigel Pharmaceuticals Shares Surged Higher Today
Todd Campbell, The Motley Fool - Motley Fool - Tue Mar 31, 4:27PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares in Rigel Pharmaceuticals ...
RIGL: 4.24 (+0.07)
Rigel Pharmaceuticals Up 10.3%, Shares Break Through Resistance (RIGL)
Comtex SmarTrend(R) - Tue Mar 31, 11:46AM CDT
Rigel Pharmaceuticals (NASDAQ:RIGL) is one of today's best performing low-priced stocks, up 10.3% to $3.70 on 1.2x average daily volume. Rigel Pharmaceuticals has traded 1.6 million shares thus far today, vs. average volume of 1.4 million shares per day. The stock has outperformed the Dow (10.3% to the Dow's -0.5%) and outperformed the S&P 500 (10.3% to the S&P's -0.4%) during today's trading.
RIGL: 4.24 (+0.07)
Nephropathy Global Clinical Trials Review, H1, 2015
M2 - Tue Mar 31, 4:15AM CDT
Research and Markets (http://www.researchandmarkets.com/research/g9gmj6/nephropathy) has announced the addition of the "Nephropathy Global Clinical Trials Review, H1, 2015" report to their offering. Nephropathy Global Clinical Trials Review, H1, 2015" provides data on the Nephropathy clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Nephropathy. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Nephropathy. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Reasons to buy - Understand the dynamics of a particular indication in a condensed manner - Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more - Obtain discontinued trial listing for trials across the globe - Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies Top Companies Participating in Nephropathy Therapeutics Clinical Trials - Pfizer Inc. - Novartis AG - Mallinckrodt plc - Rigel Pharmaceuticals, Inc. - Kliniken der Stadt Koln gGmbH - AstraZeneca PLC - Astellas Pharma Inc. - Anthera Pharmaceuticals Inc. - AbbVie Inc. For more information visit http://www.researchandmarkets.com/research/g9...ephropathy
ANTH: 4.79 (+0.10), PFE: 34.93 (+0.04), AZN: 73.35 (+0.65), ABBV: 64.52 (+0.91), RIGL: 4.24 (+0.07), NVS: 103.45 (-0.62)
Should Rigel Pharmaceuticals (RIGL) Be On Your Radar Now? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Mar 26, 7:53AM CDT
Rigel Pharmaceuticals is one such company that looks well positioned for a solid gain, but has been overlooked by investors
RIGL: 4.24 (+0.07)
Why Rigel Pharmaceuticals (RIGL) Could Be Positioned for a Surge? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Mar 23, 7:53AM CDT
Rigel Pharmaceuticals in the health care space is seeing solid activity on the earnings estimate revision front
RIGL: 4.24 (+0.07)
Cel-Sci's Cancer Immunotherapy In Phase III Is Value Opportunity
ACCESSWIRE - Thu Mar 12, 7:53AM CDT
BALTIMORE, MD / ACCESSWIRE / March 12, 2015 / Cancer immunotherapy has become today's word for treating patients with death-causing diseases, but progress and valuations within companies run a broad course. In this article, I will explain to investors how Cel-Sci Corp. (NYSE MKT:CVM) with its top drug, Multikine, now in Phase III studies for head and neck cancer, deserves to command a much higher share price than currently afforded.
ABT: 48.35 (+1.23), NWBO: 8.36 (-0.39), ZIOP: 10.88 (+0.03), PCYC: 256.98 (-0.77), CVM: 0.88 (+0.07), PFE: 34.93 (+0.04), CLDX: 28.95 (+1.08), IMGN: 9.96 (+0.01), BMY: 66.60 (-0.21), RIGL: 4.24 (+0.07), INO: 10.38 (-0.10), KITE: 57.56 (-1.43), LH: 126.26 (+0.35), ABBV: 64.52 (+0.91), PBYI: 225.63 (-4.24)
After Hours Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Mar 06, 4:42PM CST
VEEV: 27.12 (+0.28), NG: 3.56 (-0.07), CRIS: 2.88 (+0.09), EVTC: 21.61 (+0.38), GTN: 13.73 (+0.05), SM: 55.21 (+1.23), MNKD: 4.90 (-0.09), RIGL: 4.24 (+0.07), EXK: 1.86 (-0.09), WBAI: 16.75 (-0.46)
Rigel (RIGL) Down on Wider Q4 Loss, Revenues Increase Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 04, 8:10AM CST
Rigel Pharmaceuticals, Inc.'s (RIGL) fourth-quarter 2014 loss of 25 cents per share was in line with the Zacks Consensus Estimate.
AZN: 73.35 (+0.65), BMY: 66.60 (-0.21), THRX: 17.08 (+0.45), RIGL: 4.24 (+0.07)
Rigel Pharma ups revenues 48% in Q4
Seeking Alpha - at Seeking Alpha - Tue Mar 03, 8:14AM CST
RIGL: 4.24 (+0.07)
Rigel reports 4Q loss
Automated Insights - Tue Mar 03, 6:54AM CST
SOUTH SAN FRANCISCO, Calif. (AP) _ Rigel Pharmaceuticals Inc. (RIGL) on Tuesday reported a loss of $22.3 million in its fourth quarter.
RIGL: 4.24 (+0.07)
Rigel Pharmaceuticals beats by $0.01, beats on revenue
Seeking Alpha - at Seeking Alpha - Tue Mar 03, 6:32AM CST
RIGL: 4.24 (+0.07)
Rigel Announces Fourth Quarter and Year End 2014 Financial Results
PR Newswire - Tue Mar 03, 6:30AM CST
Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today reported financial results for the fourth quarter and year ended December 31, 2014. For the fourth quarter of 2014, Rigel reported a net loss of $22.3 million, or $0.25 per share, compared to a net loss of $16.9 million, or $0.19 per share, in the fourth quarter of 2013. Weighted average shares outstanding for the fourth quarters of 2014 and 2013 were 87.8 million and 87.4 million, respectively.
RIGL: 4.24 (+0.07)
The Zacks Analyst Blog Highlights: Rigel Pharmaceuticals, Exelixis and Atlas Resource Partners - Press Releases
Zacks Equity Research - Zacks Investment Research - Mon Apr 20, 8:30AM CDT
The Zacks Analyst Blog Highlights: Rigel Pharmaceuticals, Exelixis and Atlas Resource Partners
RIGL: 4.24 (+0.07), ARP: 9.04 (-0.02), EXEL: 3.12 (+0.05)
3 Momentum Picks Under $10 to Sail the Turbulent Market - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 17, 10:57AM CDT
When you combine a momentum strategy with small-cap stocks, the likelihood of gains is exponential.
RIGL: 4.24 (+0.07), EXEL: 3.12 (+0.05), ARP: 9.04 (-0.02)
Therapy Focus - Beyond Blood Pressure Control For IgA Nephropathy
EP Vantage - Seeking Alpha - Thu Apr 16, 3:54PM CDT
Phase II data from the Swedish group Pharmalink in the autoimmune disorder IgA nephropathy has shone a light on a rare, little-known condition that has no disease-modifying treatments. Tight blood pressure control to minimise the damage from the...
CCXI: 7.86 (-0.02), RIGL: 4.24 (+0.07)
BUYINS.NET: OTIV, JKD, BR, FLO, AIN, RIGL Are Seasonally Ripe To Go Up In the Next Five Weeks
M2 - Fri Apr 10, 6:59AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of On Track Innovations Ltd (NASDAQ:OTIV), iShares Morningstar Large Core Index Fund (NYSE:JKD), Big Rock Brewery Inc (NYSE:BR), Flowers Foods Inc (NYSE:FLO), Albany International Corp (NYSE:AIN), Rigel Pharmaceuticals Inc (NASDAQ:RIGL) and each have a high seasonal probability to go Up in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:
AIN: 40.36 (+0.02), BR: 53.55 (-0.04), OTIV: 1.58 (+0.03), RIGL: 4.24 (+0.07), FLO: 22.50 (-0.03), JKD: 123.64 (+0.72)
Can the Rally in Rigel Pharmaceuticals (RIGL) Shares Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Apr 09, 8:07AM CDT
Can the Rally in Rigel Pharmaceuticals (RIGL) Shares Continue?
RIGL: 4.24 (+0.07)
Healthcare stock screen of the month: Price extended, poor fundamentals
Seeking Alpha - at Seeking Alpha - Wed Apr 08, 12:05PM CDT
CRMD: 8.86 (-0.28), ADXS: 22.18 (+0.10), CYTX: 0.96 (-0.09), CNDO: 4.09 (-0.09), AMRN: 2.34 (-0.05), AVEO: 2.04 (+0.12), NVGN: 7.40 (-0.30), AXN: 1.77 (+0.01), NYMX: 1.32 (-0.08), DRRX: 2.19 (+0.10), RIGL: 4.24 (+0.07), CAPN: 6.99 (-0.29)
Technical Report on Biotech Stocks - Athersys, Dyax Corp., Rigel Pharma, Regeneron Pharma, and BioCryst Pharma
PR Newswire - Mon Apr 06, 7:55AM CDT
Editor Note: For more information about this release, please scroll to bottom.
BCRX: 10.62 (-0.09), ATHX: 1.34 (+0.01), RIGL: 4.24 (+0.07), REGN: 472.63 (+9.41), DYAX: 28.12 (+0.15)
Rigel Pharmaceuticals (RIGL) Looks Good: Stock Up 6.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Apr 01, 7:30AM CDT
Rigel Pharmaceuticals, Inc. (RIGL) was a big mover last session, as the company saw its shares rise roughly 7% on the day.
FLML: 15.84 (-0.33), RIGL: 4.24 (+0.07)
Why Rigel Pharmaceuticals Shares Surged Higher Today
Todd Campbell, The Motley Fool - Motley Fool - Tue Mar 31, 4:27PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares in Rigel Pharmaceuticals ...
RIGL: 4.24 (+0.07)
Rigel Pharmaceuticals Up 10.3%, Shares Break Through Resistance (RIGL)
Comtex SmarTrend(R) - Tue Mar 31, 11:46AM CDT
Rigel Pharmaceuticals (NASDAQ:RIGL) is one of today's best performing low-priced stocks, up 10.3% to $3.70 on 1.2x average daily volume. Rigel Pharmaceuticals has traded 1.6 million shares thus far today, vs. average volume of 1.4 million shares per day. The stock has outperformed the Dow (10.3% to the Dow's -0.5%) and outperformed the S&P 500 (10.3% to the S&P's -0.4%) during today's trading.
RIGL: 4.24 (+0.07)
Nephropathy Global Clinical Trials Review, H1, 2015
M2 - Tue Mar 31, 4:15AM CDT
Research and Markets (http://www.researchandmarkets.com/research/g9gmj6/nephropathy) has announced the addition of the "Nephropathy Global Clinical Trials Review, H1, 2015" report to their offering. Nephropathy Global Clinical Trials Review, H1, 2015" provides data on the Nephropathy clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Nephropathy. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Nephropathy. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Reasons to buy - Understand the dynamics of a particular indication in a condensed manner - Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more - Obtain discontinued trial listing for trials across the globe - Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies Top Companies Participating in Nephropathy Therapeutics Clinical Trials - Pfizer Inc. - Novartis AG - Mallinckrodt plc - Rigel Pharmaceuticals, Inc. - Kliniken der Stadt Koln gGmbH - AstraZeneca PLC - Astellas Pharma Inc. - Anthera Pharmaceuticals Inc. - AbbVie Inc. For more information visit http://www.researchandmarkets.com/research/g9...ephropathy
ANTH: 4.79 (+0.10), PFE: 34.93 (+0.04), AZN: 73.35 (+0.65), ABBV: 64.52 (+0.91), RIGL: 4.24 (+0.07), NVS: 103.45 (-0.62)
Should Rigel Pharmaceuticals (RIGL) Be On Your Radar Now? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Mar 26, 7:53AM CDT
Rigel Pharmaceuticals is one such company that looks well positioned for a solid gain, but has been overlooked by investors
RIGL: 4.24 (+0.07)
Why Rigel Pharmaceuticals (RIGL) Could Be Positioned for a Surge? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Mar 23, 7:53AM CDT
Rigel Pharmaceuticals in the health care space is seeing solid activity on the earnings estimate revision front
RIGL: 4.24 (+0.07)
Cel-Sci's Cancer Immunotherapy In Phase III Is Value Opportunity
ACCESSWIRE - Thu Mar 12, 7:53AM CDT
BALTIMORE, MD / ACCESSWIRE / March 12, 2015 / Cancer immunotherapy has become today's word for treating patients with death-causing diseases, but progress and valuations within companies run a broad course. In this article, I will explain to investors how Cel-Sci Corp. (NYSE MKT:CVM) with its top drug, Multikine, now in Phase III studies for head and neck cancer, deserves to command a much higher share price than currently afforded.
ABT: 48.35 (+1.23), NWBO: 8.36 (-0.39), ZIOP: 10.88 (+0.03), PCYC: 256.98 (-0.77), CVM: 0.88 (+0.07), PFE: 34.93 (+0.04), CLDX: 28.95 (+1.08), IMGN: 9.96 (+0.01), BMY: 66.60 (-0.21), RIGL: 4.24 (+0.07), INO: 10.38 (-0.10), KITE: 57.56 (-1.43), LH: 126.26 (+0.35), ABBV: 64.52 (+0.91), PBYI: 225.63 (-4.24)
After Hours Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Mar 06, 4:42PM CST
VEEV: 27.12 (+0.28), NG: 3.56 (-0.07), CRIS: 2.88 (+0.09), EVTC: 21.61 (+0.38), GTN: 13.73 (+0.05), SM: 55.21 (+1.23), MNKD: 4.90 (-0.09), RIGL: 4.24 (+0.07), EXK: 1.86 (-0.09), WBAI: 16.75 (-0.46)
Rigel (RIGL) Down on Wider Q4 Loss, Revenues Increase Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 04, 8:10AM CST
Rigel Pharmaceuticals, Inc.'s (RIGL) fourth-quarter 2014 loss of 25 cents per share was in line with the Zacks Consensus Estimate.
AZN: 73.35 (+0.65), BMY: 66.60 (-0.21), THRX: 17.08 (+0.45), RIGL: 4.24 (+0.07)
Rigel Pharma ups revenues 48% in Q4
Seeking Alpha - at Seeking Alpha - Tue Mar 03, 8:14AM CST
RIGL: 4.24 (+0.07)
Rigel reports 4Q loss
Automated Insights - Tue Mar 03, 6:54AM CST
SOUTH SAN FRANCISCO, Calif. (AP) _ Rigel Pharmaceuticals Inc. (RIGL) on Tuesday reported a loss of $22.3 million in its fourth quarter.
RIGL: 4.24 (+0.07)
Rigel Pharmaceuticals beats by $0.01, beats on revenue
Seeking Alpha - at Seeking Alpha - Tue Mar 03, 6:32AM CST
RIGL: 4.24 (+0.07)
Rigel Announces Fourth Quarter and Year End 2014 Financial Results
PR Newswire - Tue Mar 03, 6:30AM CST
Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today reported financial results for the fourth quarter and year ended December 31, 2014. For the fourth quarter of 2014, Rigel reported a net loss of $22.3 million, or $0.25 per share, compared to a net loss of $16.9 million, or $0.19 per share, in the fourth quarter of 2013. Weighted average shares outstanding for the fourth quarters of 2014 and 2013 were 87.8 million and 87.4 million, respectively.
RIGL: 4.24 (+0.07)
